HOOK News and Press, HOOKIPA Pharma Inc. From 02/18/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Febr...

We discussed this trend on Thursday thanks to the attention that was sparked by shares of ISPO stock. Low float penny stocks are gaining even more attention in the stock market today thanks to the massive breakout potential that they can hold. In looking at the ISPO example, the small-c...

Gainers: Creative Medical Technology (NASDAQ:CELZ) +33%. HOOKIPA Pharma (NASDAQ:HOOK) +18%. Zynex ZYXI +17%. AMN Healthcare Services (NYSE:AMN) +15%. ShockWave Medical (NASDAQ:SWAV) +10%. Losers: Baudax Bio (NASDAQ:BXRX) -11%. Nuvectis Pharma (NASDAQ:NVCT)&#...

Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +55%. Upstart Holdings (NASDAQ:UPST) +32%. Eqonex (NASDAQ:EQOS) +19%. Singularity (NASDAQ:SGLY) +15%. Alkermes (NASDAQ:ALKS) +14%. Generac Holdings (NYSE:GNRC) +14%. MYT Netherlands (NYSE:MYTE) +12%. MRC Global (NYSE:MRC) +12%. NextDecade (NASDAQ:NEXT) +1...

Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +46%. Kinnate Biopharma (NASDAQ:KNTE) +9%. Corcept Therapeutics (NASDAQ:CORT) +7%. Alkermes (NASDAQ:ALKS) +5%. Celularity (NASDAQ:CELU) +3%. Losers: Masimo (NASDAQ:MASI) -36%. Baudax Bio (NASDAQ:BXRX) -20%. ...

Buying Penny Stocks Today? Here’s What You Need to Know Buying penny stocks involves understanding what is going on in the market daily. Because penny stocks are so speculative, they tend to react heavily to any and all news that comes out. So, to make money with small-caps, ...

HOOKIPA (NASDAQ:HOOK) shares are 51% higher in after-hours trading after it amended an agreement with Gilead Sciences (NASDAQ:GILD) for the development of an arenaviral immunotherapy as part of a HIV regimen. In 2018, Gilead (GILD) licensed exclusive right to HOOKIPA's arenaviral pl...

HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafter Financial terms include $15 million initiation fee and $35 million equity commitment NEW YORK and VIEN...

NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual ...

First patient dosed with HB-200 and pembrolizumab combination for treatment of 1 st -line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation granted for HB-200 in combination with pembrolizumab for treatment of 1 st -l...